

Supplementary Table 7: Distribution of SGLT2i therapies at index date before and after propensity score matching in the SGLT2i 'add-on' vs 'switch' cohorts.

At index date	Before matching		After matching	
	SGLT2i 'add-on'	SGLT2i 'switch'	SGLT2i 'add-on'	SGLT2i 'switch'
Total SGLT2i	7,167	4,891	4,843	4,843
Dapagliflozin	2,673 (37.3%)	1,935 (39.6%)	1,774 (36.6%)	1,911 (39.5%)
Empagliflozin	4,494 (62.7%)	2,956 (60.4%)	3,069 (63.4%)	2,932 (60.5%)

Please note that canagliflozin is not marketed in Hungary, and ertugliflozin was not yet available at the time of analysis.